Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
Fintel on MSN

B Riley Securities initiates coverage of Palisade Bio (PALI) with buy recommendation

Fintel reports that on January 9, 2026, B. Riley Securities initiated coverage of Palisade Bio (NasdaqCM:PALI) with a Buy recommendation. Analyst Price Forecast Suggests 499.50% Upside As of December ...

Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results

We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Palisade Bio Inc. (NASDAQ:PALI) is one of the best ...

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and ...